# US 2024/0255491 A1 · Treatment methods having reduced drug-related toxicity and methods of identifying the likelihood of patient harm from prescribed medications

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0255491 A1
- Document ID: US20240255491A1
- Status: Published application
- Kind: A1
- Application number: 18/502,543
- Filed: 2023-11-06
- Published: 2024-08-01
- Earliest claimed: 2016-05-19
- Assignees: Tabula Rasa Healthcare, Inc.
- Applicants: Tabula Rasa Healthcare, Inc.
- Inventors: Jacques Turgeon; Lauren E. Steffen; Gabriel Badea; Veronique Michaud
- Web page: https://patentgrep.com/patent/US20240255491A1

## CPC

- G01N 33/5014: {for testing toxicity}
- A61B 5/361: Detecting fibrillation
- A61B 5/363: Detecting tachycardia or bradycardia
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 49/0004: {Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/06: Antiarrhythmics
- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- G01N 2800/326: Arrhythmias, e.g. ventricular fibrillation, tachycardia, atrioventricular block, torsade de pointes
- G01N 2800/50: Determining the risk of developing a disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of determining whether specific drugs or patients carry an increased risk of causing or developing, respectively, long QT syndrome or Torsades de Pointes and methods of treating such patients.

## Claims

### Claim 1

A method for determining a propensity of a medication for causing long QT syndrome or Torsades de Pointes by determining a drug-specific index for the medication, the method comprising the steps of:
calculating a first index variable for the medication by determining:
an IC50 value for block of one or more of IKr and IKs for the medication, a Cmax of the medication at a test dose, a daily dose amount of the medication, a protein binding value for the medication at a target protein, and a drug-drug interaction coefficient (DDIC) for the medication;
measuring calculating a second index variable for the medication by determining:
an IC50 value for block of CaV1.2 current for the medication, and
the IC50 value for block of one or more of IKr and IKs for the medication;
calculating a third index variable for the medication by determining:
an IC50 value for block of NaV1.5 current for the medication, and the IC50 value for block of one or more of IKr and IKs for the medication;
calculating a fourth index variable for the medication based on whether the medication is an inhibitor of hERG trafficking; and
combining the first, second, third, and fourth index variables to provide the drug-specific index, which is indicative of the medication's risk of causing long QT syndrome or Torsades de Pointes.

### Claim 2

A method for determining whether a patient undergoing treatment with a compound has an increased risk of long QT syndrome or Torsades de Pointes by determining a patient-specific score, the method comprising one or more steps of:
(a) determining a first risk variable value based on the patient's gender and age;
(b) measuring the patient's heart rhythm comprising detecting one or more of sinus rhythm, atrial fibrillation, sick sinus syndrome, pause, and heart rate to generate a second risk variable value;
(c) detecting a potassium level in the patient to generate a third risk variable value;
(d) detecting a magnesium level in the patient to generate a fourth risk variable value;
(e) detecting the presence of one or more diuretics in the patient to generate a fifth risk variable value;
(f) detecting the presence of one or more antiarrhythmics in the patient to generate a sixth risk variable value;
(g) measuring a drug-specific index for one or more drug therapeutics in the patient's treatment regimen to generate a seventh risk variable value; and
(h) measuring the patient's QT interval to generate an eight risk variable value, and
the method further comprising combining the determined risk variable values from the one or more of steps (a) through (h) to obtain a patient-specific score, wherein a patient-specific score under a predetermined threshold value is indicative of the patient having an increased risk of long QT syndrome and/or Torsades de Pointes.

### Claim 3

A method of treating patients having an increased risk of developing long QT syndrome or Torsades de Pointes due to a patient-specific score exceeding a predetermined threshold value, the method comprising administering a therapeutically effective amount of a medication.

### Claim 4 (depends on 3)

The method of claim 3, wherein the medication is a potassium salt.

### Claim 5 (depends on 3)

The method of claim 3, wherein the medication is a magnesium salt.

### Claim 6

(canceled)

### Claim 7 (depends on 3)

The method of claim 3, wherein the medication is selected from the group consisting of Albuterol, Alfuzosin, Amantadine, Amiodarone, Amitriptyline, Amphetamine, Arsenic trioxide, Astemizole, Atazanavir, Atomoxetine, Azithromycin, Bepridil, Chloral hydrate, Chloroquine, Chlorpromazine, Ciprofloxacin, Cisapride, Citalopram, Clarithromycin, Clomipramine, Clozapine, Cocaine, Desipramine, Dexmethylphenidate, Diphenhydramine, Diphenhydramine, Disopyramide, Dobutamine, Dofetilide, Dolasetron, Domperidone, Dopamine, Doxepin, Dronedarone, Droperidol, Ephedrine, Epinephrine, Erythromycin, Escitalopram, Escitalopram, Famotidine, Felbamate, Fenfluramine, Flecamide, Fluconazole, Fluoxetine, Foscarnet, Fosphenyloin, Galantamine, Gatifloxacin, Gemifloxacin, Granisetron, Halofantrine, Haloperidol, Ibutilide, Imipramine, Indapamide, Isoproterenol, Isoproterenol, Isradipine, Itraconazole, Ketoconazole, Lapatinib, Lapatinib, Levalbuterol, Levofloxacin, Levomethadyl, Lisdexamfetamine, Lithium, Mesoridazine, Metaproterenol, Methadone, Methylphenidate, Midodrine, Moexipril/HCTZ, Moxifloxacin, Nicardipine, Nilotinib, Norepinephrine, Nortriptyline, Octreotide, Ofloxacin, Ondansetron, Oxytocin, Paliperidone, Paroxetine, Pentamidine, Perflutren lipid microspheres, Phentermine, Phenylephrine, Phenylpropanolamine, Pimozide, Probucol, Procainamide, Protriptyline, Pseudoephedrine, Quetiapine, Quinidine, Ranolazine, Risperidone, Ritodrine, Ritonavir, Roxithromycin, Salmeterol, Sertindole, Sertraline, Sibutramine, Solifenacin, Sotalol, Sparfloxacin, Sunitinib, Tacrolimus, Tamoxifen, Telithromycin, Terbutaline, Terfenadine, Thioridazine, Tizanidine, Tolterodine, Trazodone, Trimethoprim-Sulfa, Trimipramine, Vandetanib, Vardenafil, Venlafaxine, Voriconazole, Ziprasidone, and a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 3)

The method of claim 3, further comprising treating a patient with a the medication, wherein the medication is determined to increase the risk of long QT syndrome or Torsades de Pointes as a result of the medication's drug-specific index, the method comprising the steps of:
administering a pharmaceutical composition to the patient comprising a therapeutically effective amount of the medication or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier;
determining whether the patient has an increased risk of developing long QT syndrome or Torsades de Pointes due to a patient-specific score that is indicative of an increased risk of developing long QT syndrome or Torsades de Pointes; and
halting treatment of the patient with the pharmaceutical composition.

### Claim 9 (depends on 8)

The method of claim 8, further comprising the step of administering an additional pharmaceutical composition to the patient that does not include the medication.

### Claim 10 (depends on 9)

The method of claim 9, wherein the additional pharmaceutical composition comprises an additional drug that has a drug-specific index at or above a predetermined threshold value.

### Claim 11 (depends on 9)

The method of claim 9, wherein the additional pharmaceutical composition comprises a LQTS medicament configured to treat Long QT Syndrome and/or Torsades de Pointes.
